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Progression of malignant brain tumors is dependent upon vascularity and is associated with altered ganglioside composition
and distribution. Evidence is reviewed showing that the simple monosialoganglioside, GM3, possesses powerful antiangiogenic
action against the highly vascularized CT-2A mouse astrocytoma, which primarily expresses complex gangliosides. Brain tumors
expressing high levels of GM3 are generally less vascularized and grow slower than tumors that express low levels of GM3.
GM3 inhibits angiogenesis through autocrine and paracrine eﬀects on vascular endothelial growth factor (VEGF) and associated
receptors. GM3 should be a clinically useful compound for managing brain tumor angiogenesis.
1.Introduction
Malignant brain cancer persists as a catastrophic illness and
is the second leading cause of cancer death in children
[1–4]. The failure to eﬀectively manage malignant brain
cancer has been due in large part to the highly invasive
nature of the disease and to the unique anatomical and
metabolic environment of the brain, which prevents the
large-scale resection of tumor tissue and impedes the
delivery of therapeutic drugs. Invasion/metastasis involves
the dissemination of tumor cells from the primary neoplasm
to surrounding tissue and distant regions. In addition, the
invasive cells establish a microenvironment facilitating col-
onization (angiogenesis and further proliferation), resulting
in macroscopic malignant secondary tumors [5, 6]. Tumor
cell invasion is correlated with tumor angiogenesis (vascu-
larity), as prognosis is generally worse for brain tumors that
are more vascular than for those that are less vascular [7–9].
Consequently, therapies that can simultaneously target both
angiogenesis and invasion could provide eﬀective longer-
term management of malignant brain cancer.
2. Glycosphingolipids and Angiogenesis
Gangliosides are a family of cell surface-enriched glycosph-
ingolipids that have long been implicated in tumorigenesis
[10–12]. These molecules contain an oligosaccharide head
group attached to a lipophilic ceramide, consisting of a
sphingosine base and a long-chain fatty acid (Figure 1). The
presence of sialic acid (N-acetylneuraminic acid, NeuAc)
distinguishesthegangliosidesfromotherglycosphingolipids.
Gangliosides are anchored in the outer surface of plasma
membranes through their ceramide moiety, which allows the
headgrouptomodulatenumerouscellsurfaceeventssuchas
growth, migration, adhesion, and signaling [12–15].
The structurally simple monosialoganglioside GM3
contains a single terminal sialic acid (Figure 1). N-
acetylneuraminic acid is the predominant sialic acid species
expressed in mammalian brain gangliosides [16, 17]. In
contrast to N-acetylneuraminic acid, N-glycolylneuraminic
acid is a predominant sialic acid species expressed in
gangliosides from nonneural tissues of most nonhuman
species (rodents, bovine, etc.) [17]. As humans lack the
gene for the synthesis of N-glycolylneuraminic acid [18, 19],
expression of N-glycolylneuraminic acid in gangliosides of
human cells or tissues is attributed to contamination from
exposure to nonhuman serum or from diet [17, 20, 21]. The
involvement of gangliosides in angiogenesis is dependent on
the intact molecules as neither asialo species nor sialic alone
inﬂuence angiogenesis [22].
GM3 modulates the function of several receptors impli-
cated with angiogenesis to include those for the insulin-
like growth factor-1 (IGF-1), basic ﬁbroblast growth factor
(b-FGF), epidermal growth factor (EGF), platelet-derived2 Journal of Oncology
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Figure 1: Structure of Ganglioside GM3 (NeuAc-alpha 2→ 3Gal-beta1 → 4Glc-beta1 → 1  Ceramide) (from [14] with permission).
Table 1: Association of GM3 levels to the vascularity of experimen-
tal brain tumors∗.
Ganglioside Distribution Vascularity
Brain Tumors GM3 Complex Gangliosides
Mouse
EPEN High Low Low
CBT-1 High Low Low
CBT-3 High Low Low
CBT-4 Low high High
CT-2 Low High High
CT-2A Low High High
Human
U87MG Low High High
∗All mouse brain tumors were produced from implantation of 20-
methylcholantherene into the ventricle (EPEN), thecerebrum (CT), or the
cerebellum (CBT) of C57BL/6J mice as we previously described [43].
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Figure 2: Pathway for the synthesis of ganglioside GM2 from GM3
by GalNAc-T. GalNAc-T adds a beta-linked N-acetylgalactosamine
residue to the galactose of GM3 to form GM2, a key step required
for the synthesis of complex gangliosides, GM2, GM1, and GD1a.
Antisense targeting of the GalNAc-T gene reduces GD1a content,
while increasing GM3 content [7].
growth factor (PDGF), vascular endothelial growth factor
(VEGF), and cell adhesion molecules including the integrins
[7, 12, 23–28]. GM3 also reduces proliferation and enhances
apoptosis of rapidly proliferating neural stem cells [29].
Furthermore, Alessandri, Ziche, and coworkers originally
found that several complex gangliosides (GM2, GM1, GD3,
GD1a, GD1b, and GT1b) enhanced the action of angiogenic
inducers, whereas ganglioside GM3 was inhibitory [30–32].
These observations suggest that GM3 could have therapeutic
potential against tumor cell proliferation and angiogenesis.
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Figure 3: High-performance thin-layer chromatographic analysis
of ganglioside distribution in the CT-2A astrocytoma: Control
untransfected CT-2A (C), CT-2A transfected with empty vector
alone (V), and CT-2A transfected with the antisense sequence
to the GalNAc-T gene (T). Synthesized gangliosides appear as
double bands due to ceramide structural heterogeneity. Analysis
of synthesized gangliosides and standards (left lane) was as we
described [7]. Knockdown of the GalNAc-T gene elevated GM3
content, while reducing GD1a content in the antisense T cells.
The ratio of GM3 to the proangiogenic gangliosides
GD3 and GD1a (GM3/GD3; GM3/GD1a) is lower in more
metastatic and aggressive tumors than that in less metastatic
tumors [7, 33–35], suggesting that elevated expression
of complex gangliosides enhances tumor malignancy. In
contrasttomosthumangliomatumortissues,whichcontain
high levels of the pro-angiogenic ganglioside GD3 [36–41],
GD3 is not heavily expressed in mouse brain tumors or
in most cultured human brain tumor cells [17, 42–44].
Although GM3 is also expressed in malignant human brain
tumors,wethinkthatGM3expressioninthesetumorsmight
serve to regulate or to counteract the pro-angiogenic action
of GD3 and other complex gangliosides.
3. Evidence Supportingthe Anti-Angiogenic
Action of GM3 in Brain Cancer
Table 1 summarizes data from our previous studies on
the association of GM3 expression with the angiogenicJournal of Oncology 3
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Figure 4: Ganglioside shift reduces growth, VEGF gene and protein expression, and vascularity in the CT-2A astrocytoma: Control
untransfectedCT-2A(C),CT-2Atransfectedwithemptyvectoralone(V),andCT-2AtransfectedwiththeantisensesequencetotheGalNAc-
T gene (T). (a) The values are expressed as mean mg wet weight±SE.∗: signiﬁcant compared to control C and V tumors at the P<. 01 level.
CT-2A (n = 10), CT-2A/V (n = 12), and CT-2A/TNG (n = 14) independent tumors. (b) RT-PCR and Western blot for VEGF. Other
details are in [7]. (c) Vascularity determined using factor VIII-immunostained microvessels per ×200 ﬁeld (hpf, high-powered ﬁeld) from
tissue sections as we described [7].4 Journal of Oncology
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Figure 5: Ganglioside shift reduces VEGF, HIF-1α, and NP-1 gene expression in CT-2A- cultured cells: Control untransfected CT-2A (C),
CT-2A transfected with empty vector alone (V), and CT-2A transfected with the anti-sense sequence to (a) the GalNAc-T gene (T). VEGF
(multiple splice variants: 400–600bp), HIF-1α (365bp), and NP-1 (551bp) ampliﬁcation products were detected in each tumor cell line.
Experimental conditions are as we described [7] .T h eg e n et oβ-actin levels are expressed as the means of three independent samples±SE.∗:
Signiﬁcant compared to control C and V cells at (b) the P<. 01.
Control GM3 treated
Figure 6: GM3 reduces CT-2A tumor vascularity when added to the tumor microenvironment. Small fragments of the CT-2A tumor were
grown in Matrigel that contained either no GM3 (control) or GM3 (40μM). The tumor was grown in Matrigel for approximately two weeks
in the ﬂank of the syngeneic host C57BL/6 mice according to our standard procedures [7, 34]. Florid vascularization and the number and
size thrombotic vessels were noticeably less in the presence than in the absence of GM3. Similar results were found in two independent
experiments.
properties of multiple experimental mouse and human
brain tumor models [17, 44, 45]. This survey shows that
brain tumors with high GM3 expression are less angiogenic
(vascularized) than brain tumors with low GM3 expression.
GM3 expression was also correlated with greater cell-cell
adhesion and slower growth [14, 44]. We later showed
that the gene-linked knockdown of GM3 expression in
the experimental ependymoblastoma (EPEN) tumor, which
contains GM3 as the only ganglioside, increased vascularity
(angiogenesis) [34]. An opposite eﬀect was observed in the
highly angiogenic CT-2A astrocytoma when we upregulated
GM3 expression (below). These and other ﬁndings led us
to conclude that the ratio of GM3 to complex gangliosides
(GM1, GD1a, GT1b) can inﬂuence the angiogenic propertiesJournal of Oncology 5
Control GD1a (40 μM) GM3+GD1a (40 μMe a c h )
Figure 7: GM3 inhibits the pro-angiogenic eﬀects of GD1a in the in vivo Matrigel assay. Matrigel alone (control) or containing GD1a or
GD1a with GM3 was injected subcutaneously (s.c.) in SCID mice as we described [49]. Plugs were photographed (12.5×)o nd a y7a f t e r
Matrigel injection.
of a broad range of brain tumor types and are consistent
with previous ﬁndings on the role of GM3 in other systems
[22, 29, 32, 41, 46–49].
4. Anti-AngiogenicAction of GM3 in
the CT-2A Astrocytoma
The CT-2A astrocytoma was produced following implan-
tation of the chemical carcinogen, 20-methylcholanthrene,
into the cerebral cortex of C57BL/6J mouse according to
the procedures of Zimmerman and Arnold [44, 50]. The
CT-2A tumor grows rapidly, is deﬁcient in the phosphatase
and tensin homologue/tuberous sclerosis complex 2, and is
highly angiogenic [7, 51, 52]. We used an antisense construct
to inhibit GalNAc-T expression in CT-2A cells as shown
in (Figure 2). This caused a signiﬁcant shift in ganglioside
distribution, elevating GM3 content while reducing GD1a
content (Figure 3).
Theshiftingangliosidedistributionsigniﬁcantlyreduced
growth, VEGF gene and protein expression, and blood
vessel density in the orthotopically grown CT-2A tumors
(Figure 4). Moreover, the shift in ganglioside distribution
reduced gene expression for hypoxia inducible factor 1a
(HIF-1α) and the VEGF coreceptor neruropilin-1 (NP-1)
in the CT-2A cultured cells (Figure 5). This is interesting
as HIF-1α is a transcription factor that regulates VEGF
expression through the PI-3k/Akt signaling pathway [51, 53–
55]. Viewed collectively, these data show that endogenous
upregulation of GM3 reduces growth and angiogenesis in
the rapidly growing and highly vascularized CT-2A mouse
astrocytoma.
It was initially unclear, however, whether it was the
elevation of GM3, the reduction of the pro-angiogenic
ganglioside GD1a, or the change in GM3/GD1a ratio that
was responsible for the reduction in CT-2A angiogenesis. It
is well documented that gangliosides are shed from tumor
cells into the microenvironment where stromal (endothelial)
cells take them up to inﬂuence tumor progression [56–
60]. Our most recent ﬁndings show that GM3, by itself,
markedly reduces CT-2A vascularity when grown in the
in vivo Matrigel model (Figure 6). These ﬁndings suggest
that GM3 could be applied as a drug therapy directly
to the tumor site and to surrounding areas following
surgical tumor resection in humans. Alternatively, GM3
could be applied in liposomes as a pharmacotherapy for
preformed tumors. Our ﬁndings in brain tumor cells are
also consistent with previous ﬁndings in rabbit cornea
showing that GM3 applied directly to tissue is anti-
angiogenic [32]. Viewed, collectively, our ﬁndings indicate
that GM3 has powerful anti-angiogenic action against the
CT-2A astrocytoma when present in the microenvironment
and can counteract the pro-angiogenic eﬀects of complex
gangliosides.
Further evidence for a direct anti-angiogenic role of
GM3 came from our recent studies with human umbilical
vein endothelial cells, HUVEC. We found that GM3, by
itself, signiﬁcantly suppresses VEGF-induced proliferation
and migration of HUVEC [49]. Moreover, GM3 signiﬁcantly
blocks GD1a-induced angiogenesis in the in vivo Matrigel
assay (Figure 7). GD1a is a complex ganglioside associated
with enhanced angiogenesis [7, 61]. The suppression of
VEGF receptor 2 and Akt phosphorylation underlies the
anti-angiogenic eﬀect of GM3 on HUVEC (Figure 8).
Additionally, the EPEN tumor, which expresses only GM3,
has few blood vessels relative to tumors that express complex
gangliosides [44, 45]. Consistent with our ﬁndings, Chung
and coworkers recently showed that GM3 could suppress
angiogenesis through the inactivation of VEGF-induced sig-
naling by direct interaction with VEGFR-2 [47]. GM3 treat-
ment could also reduce in vivo vascularity in the Lewis lung
carcinoma model [47], while van Cruijsen et al. showed that
vascularity was less and patient survival was better for non-
small cell lung carcinomas that contained more GM3 than
less GM3 [62]. Hence, GM3 is anti-angiogenic through its
inhibition of the proangiogenic actions of complex ganglio-
sidesaswellasthroughitsdirectinhibitionofendothelialcell
growth.6 Journal of Oncology
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Figure 8: GM3 inhibits VEGFR-2 and Akt phosphorylation in HUVEC. HUVECs were incubated with GM3 (100ng/ml) in endothelial
basal medium (EBM) for 24 hours and were then stimulated with VEGF (100ng/ml) for 5minutes as we described [49]. (a) Cell lysates
were prepared and measurement of VEGFR-2 and Akt phosphorylation over total was analyzed using Western blots [49]. (b) VEGFR-2
and (c) Akt phosphorylation were signiﬁcantly lower in GM3-treated HUVEC than in control HUVEC (P<. 001). Values are expressed as
means ±SEM (n = 3 independent experiments).
In summary, our results show that GM3 inhibits brain
tumor angiogenesis. GM3 targets both tumor cells and
endothelial cells. Although GM3 is elevated in human
malignant brain tumors, its concentration is less than
that of complex gangliosides especially GD3. We suggest
that increasing the ratio of GM3 to complex gangliosides
may be eﬀective in reducing angiogenesis and growth in
human glioblastomas. Our ﬁndings suggest that pharma-
cological application of GM3 is warranted as a potential
nontoxic anti-angiogenic therapy for malignant brain
cancer.
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